CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Follow-up of High Risk Non-muscle Invasive Bladder Tumor
Jun Hyuk Hong
Korean J Urol Oncol. 2008;6(3):107-110.   Published online 2008 December 1

Excel Download

BCG versus Cystectomy for High Risk, High Grade Non Muscle Invasive Bladder Cancer
Bladder Cancer. 2021;7(1):107-108   Crossref logo
Link1

Follow-up in non-muscle invasive bladder cancer: facts and future
World Journal of Urology. 2020;   Crossref logo
Link1 Link2 Link3

Risk-stratified surveillance and cost effectiveness of follow-up after trans-urethral resection of bladder tumor in patients with primary non-muscle-invasive bladder cancer
European Urology Supplements. 2019;18(1):e951-e952   Crossref logo
Link1 Link2

UP-01.052 Outcome of Treatment of High-Risk, Non Muscle-Invasive Bladder Cancer with Mitomycin Hyperthermia with a Minimum Follow-Up of Two Years
Urology. 2011;78(3):S201   Crossref logo
Link1 Link2

High Risk NMIBC and TURBT
Management of Non-Muscle Invasive Bladder Cancer. 2019;263-264   Crossref logo
Link1

MP-20.14: Combined Thermo-Chemotherapy (Synergo®) in Non Muscle Invasive Bladder Cancer (NMIBC): 8 Year Follow Up of a Prospective Monocentric Cohort Study
Urology. 2009;74(4):S145   Crossref logo
Link1 Link2

Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer
Journal of Urology. 2017;197(1):52-54   Crossref logo
Link1 Link2

Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer
European Urology Supplements. 2009;8(7):556-562   Crossref logo
Link1 Link2

Active Surveillance for Low-Risk Non-Muscle Invasive Bladder Cancer
Treating Urothelial Bladder Cancer. 2018;31-34   Crossref logo
Link1

PD19-06 HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) TREATED WITH SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION MITOMYCIN-C (EMDA-MMC): 2% DISEASE-SPECIFIC MORTALITY AT 4 YEARS' FOLLOW-UP
Journal of Urology. 2017;197(4S):   Crossref logo
Link1 Link2